Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Gross Margin (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Gross Margin for 15 consecutive years, with 34.84% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 370.0% year-over-year to 34.84%, compared with a TTM value of 32.33% through Oct 2025, up 587.0%, and an annual FY2025 reading of 32.33%, up 587.0% over the prior year.
  • Gross Margin was 34.84% for Q4 2025 at Pharma-Bio Serv, up from 29.25% in the prior quarter.
  • Across five years, Gross Margin topped out at 34.84% in Q4 2025 and bottomed at 22.5% in Q1 2024.
  • Average Gross Margin over 5 years is 28.05%, with a median of 27.13% recorded in 2021.
  • The sharpest move saw Gross Margin crashed -759bps in 2024, then surged 858bps in 2025.
  • Year by year, Gross Margin stood at 26.78% in 2021, then fell by -11bps to 23.9% in 2022, then rose by 8bps to 25.84% in 2023, then increased by 21bps to 31.14% in 2024, then rose by 12bps to 34.84% in 2025.
  • Business Quant data shows Gross Margin for PBSV at 34.84% in Q4 2025, 29.25% in Q3 2025, and 33.87% in Q2 2025.